Non-ischemic Dilated Cardiomyopathy
Conditions
Brief summary
Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for Sudden Cardiac Death (SCD) prevention in patients with non-ischemic dilated cardiomyopathy with Left Ventricular Ejection Fraction (LVEF) ≤35%
Detailed description
Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for SCD prevention in patients with non-ischemic dilated cardiomyopathy with LVEF≤35% Randomization will be 1:1 and patients are allocated to either control strategy or intervention strategy. In the control strategy group, patients will get an Implantable Cardioverter Defibrillator (ICD) implanted. Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a Dilated Cardiomyopathy DCM-causing pathogenic or likely pathogenic genetic variants or Late Gadolinium Enhancement (LGE) in Cardiac Magnetic Resonance (CMR). Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
Interventions
OTHERControl Strategy
ICDs will be implanted in all patients according to current recommendations
OTHERPersonalized precision ICD implantation Strategy based in genetic findings and CMR results
Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
Sponsors
Instituto de Salud Carlos III
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years at the time of screening. * Previously established diagnosis of Non-ischemic DCM * Optimised medical treatment at maximum tolerated doses for at least 3 months prior to the screening date. * NYHA functional class II-III. * LVEF ≤ 35% documented by CMR as study procedure. * Life expectancy greater than 12 months.
Exclusion criteria
* History of coronary artery disease justifying the presence of ventricular dysfunction, defined as: history of coronary revascularisation or presence of significant coronary stenosis (≥50% in left main or ≥70% in a major epicardial artery) on invasive or non-invasive coronary angiography (coronary CT) * Left ventricular dysfunction attributed to congenital heart disease, valvular disease, alcohol abuse or chemotherapy. * Hypertrophic or infiltrative cardiomyopathy, active myocarditis or constrictive pericarditis. * History of recovered sudden death or sustained ventricular tachycardia. * NYHA functional class IV. * Waiting list for cardiac transplantation in emergency 0. * Receiver of a solid organ transplant (lung, liver, heart or kidney).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite end-point of all cause death, hospitalization due to device-related complications, and non-fatal major arrhythmic events. | 4 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SCD | 4 years | — |
| Hospitalisation for device-related complications | 4 years | — |
| All-cause death | 4 years | — |
| cost-effectiveness | 4 years | Incremental Cost-effectiveness ratio (ICER) of personalized ICD allocation strategy in non-ischemic DCM \[ Time Frame: The time horizon of the evaluation will be limited to 4 years \] The ICER of the personalized ICD allocation strategy compared with standard strategy is defined as the ratio between the variation in costs and the variation in effectiveness between both strategy groups. In the personalized strategy group, costs will include those related to personalization tests (CMR and genetic analysis) plus costs related to implanting and carrying an ICD (in the number of patients who eventually receive a device). In the control group, costs will include only the latter concept. Costs will be measured in Euros. The variation in effectiveness will be measured both in terms of life years gained, measured in years, and in terms of quality of life gained, measured in QALY. In the first case, ICER will be measured as Euros/year; in the second, it will be measured as Euros/QALY. |
| Quality of life assessed by KCCQ, EQ-5D and HADS | 4 years | — |
| Non-fatal major arrhythmic events | 4 years | — |
Countries
Spain
Contacts
Primary ContactMaria de la Iglesia
Backup ContactProjects Department (CIBER)
Outcome results
None listed